title: Co-modification of IL-2-TNF alpha fusion gene and B7.1 gene to murine breast tumor cells leads to improved tumor rejection and vaccine effect.
abstract: OBJECTIVE
  To improve the vaccine potency of gene-modified tumor cells.
  
  
  METHODS
  Using recombinant adenoviruses, we expressed the B7.1 gene in murine breast tumor cell line EMF6 and a subline previously transfected with retrovirus vector XdF harboring the IL-2-TNF alpha fusion gene.
  
  
  RESULTS
  Immunization/challenge experiments demonstrated that IL-2-TNF alpha/B7.1 co-modified tumor cells possessed a lower tumorigenicity in vivo and an improved tumor-specific vaccine potency compared with single gene transfectant (P < 0.05). Three weeks after immunization with a variety of tumor cells, the mixed lymphocyte and tumor cells reaction assay (MLTB) and 51Cr-release assay were performed to test cellular immunity function. The results indicated that IL-2-TNF alpha and B7.1 together induced a more potent antitumor immune response than either molecule alone, 25% higher than IL-2-TNF alpha and 20% higher than B7.1, respectively.
  
  
  CONCLUSIONS
  The IL-2-TNF alpha fusion gene and B7.1 gene act in concert to improve their antitumor effectiveness.
authors.affiliation: Department of Genetics, Institute of Laboratory Animal Science, PUMC & CAMS, Beijing 100021, China. Xuefeng_Liu@hotmail.com
authors.forename: X
authors.initials: X
authors.lastname: Liu
authors.forename: L
authors.initials: L
authors.lastname: Zhang
authors.forename: M
authors.initials: M
authors.lastname: Zhang
authors.forename: Y
authors.initials: Y
authors.lastname: Ma
authors.forename: X
authors.initials: X
authors.lastname: Xu
authors.forename: Y
authors.initials: Y
authors.lastname: Cai
mesh_terms: D000818:Animals; D018122:B7-1 Antigen / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D019496:Cancer Vaccines / Q000235:genetics / Q000276:immunology*; D002455:Cell Division / Q000276:immunology; D002460:Cell Line; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007376:Interleukin-2 / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D008325:Mammary Neoplasms, Experimental / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000378:metabolism; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000166:cytology / Q000276:immunology; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology* / Q000378:metabolism
chemical_list: D018122:B7-1 Antigen; D019496:Cancer Vaccines; D007376:Interleukin-2; D012333:RNA, Messenger; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha